Current Issues of Pharmacy and Medical Sciences

The activity of micafungin against clinical isolates of non-albicans Candida spp.

Curr Issues Pharm Med Sci., Vol. 28, No. 1, Pages 13-16

Anna Biernasiuk1*, Ewelina Dobiecka1, Grażyna Zdzienicka2, Anna Malm1

1 Department of Pharmaceutical Microbiology, Medical University of Lublin, Chodzki 1, 20-093 Lublin, Poland
2 Department of Diagnostics Microbiology, Independent Public Teaching Hospital No 1, Lublin, Staszica 16

DOI: 10.1515/cipms-2015-0033



Infections caused by non-albicans Candida spp. are an important medical problem in people from risk groups, e.g. hematooncological patients. The aim of this paper was to analyse the in vitro activity of micafungin against 30 clinical isolates of non-albicans Candida spp. (C. glabrata, C. famata, C. tropicalis, C. inconspicua, C. lusitaniae, C. parapsilosis, C. krusei) by way of the E-test procedure, allowing determination of minimal inhibitory concentration (MIC). Data presented in this paper indicate that most of the studied clinical isolates – 27 (90%) showed sensitivity to micafungin, with MIC values ranging from 0.004 to 2 mg/l, while 3 (10%) isolates, including 2 isolates of C. tropicalis and 1 isolate of C. famata, were resistant to micafungin, with MIC values > 32 mg/l. The MIC50 and MIC90 values of micafungin, defined as MIC inhibited growth of 50% or 90% of the isolates studied, were 0.008 mg/l or 2 mg/l, respectively. In the case of C. glabrata isolates, MICs ranged from 0.004 to 0.016 mg/l, while MIC50 was 0.004 mg/l and MIC90 – 0.008 mg/l. Our data confirm the utility of micafungin for the therapy of the infections caused by non-albicans Candida spp., especially C. glabrata


Full Text


non-albicans Candida spp., E-test, minimal inhibitory concentration (MIC).


July 2020

Mon Tue Wed Thu Fri Sat Sun
    01 02 03 04 05
06 07 08 09 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31